Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by palinc2000on Feb 06, 2024 10:37am
106 Views
Post# 35865194

RE:Why not more

RE:Why not more

I think you are referring to the post below..At that time I was expecting a full FDA approval for F8 which  is a pre requisite to start the  Nash Trial with a partner .... I have expectations for  THTX meetiing the  revenue guidance but the delay in F8 will not give rise to increased optimism for Egrifta sales increase .... TH1902 ? I have no expectations since we dont know anything ... 
My hope is that they do share the sales pitch they made to convince IQ and Soleus to invest...
https://stockhouse.com/companies/bullboard?symbol=t.th&postid=35829212

PWIB123 wrote: I saw THTX's earnings call and business update announcement this morning, and they only included a special statement about providing clarification and additional details around the CRL?  They set zero expectation for any announcements regarding TH-1902.

I know palinc2000 was expecting market making news on this call.  Has anyone heard anything about TH-1902?  It would appear they are going to skip over TH-1902 again on this conference call.  Maybe they just didn't highlight it like the CRL, but there's been no news after announcing all locations were actively recruiting.

 

<< Previous
Bullboard Posts
Next >>